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Abstract
Previous studies have revealed that HIV infected individuals possess circulating CD4+CD8+ (DP)
T-cells specific for HIV antigens. In the present study, we analyzed the proliferation and
functional profile of circulating DP T-cells from 30 acutely HIV infected individuals and 10
chronically HIV infected viral controllers. The acutely infected group had DP T-cells which
showed more proliferative capability and multifunctionality than both their CD4+ and CD8+ T-
cells. DP T-cells were found to exhibit greater proliferation and higher multifunctionality
compared to CD4 T-cells in the viral controller group. The DP T-cell response represented 16% of
the total anti-HIV proliferative response and greater than 70% of the anti-HIV multifunctional
response in the acutely infected subjects. Proliferating DP T-cells of the acutely infected subjects
responded to all HIV antigen pools with equal magnitude. Conversely, the multifunctional
response was focused on the pool representing Nef, Rev, Tat, VPR and VPU. Meanwhile, the
controllers’ DP T-cells focused on Gag and the Nef, Rev, Tat, VPR and VPU pool for both their
proliferative and multifunctional responses. Finally, we show that the presence of proliferating DP
T-cells following all HIV antigen stimulations is well correlated with proliferating CD4 T-cells
while multifunctionality appears to be largely independent of multifunctionality in other T-cell
compartments. Therefore, DP T-cells represent a highly reactive cell population during acute HIV
infection, which responds independently from the traditional T-cell compartments.
Introduction
Immature T cells express both CD4 and CD8 while undergoing thymic development(1).
Traditionally it was believed that expression of either CD4 or CD8 was permanently lost
once T-cells transitioned to naïve T-cell status and exited the thymus. Despite this, it has
been observed that both healthy and diseased humans, chickens, monkeys, mice, rats and
pigs exhibit a circulating pool of CD4+CD8+ double positive (DP) T-cells(2–7). The DP
population generally represents around 3% of circulating T-cells but shows considerable
variability across individuals(3). In patients suffering from various neoplastic and infectious
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diseases, as well as in some ostensibly healthy individuals, circulating DPs can represent up
to 43% of circulating T-cells(8–9).
Circulating DPs have often been thought to arise from thymic leakage of immature T-
cells(2, 10). Nonetheless, sporadic studies have examined the origins and functional abilities
of extra-thymic DPs. DPs have been shown to localize to the sites of inflammatory processes
in a variety of autoimmune disorders as well as in infectious diseases, such as HCV(9, 11–
12). It has been reported that DPs with a highly activated memory phenotype and expressing
both HIV co-receptors CCR5 and CXCR4 are located in the intestine, where HIV replication
preferentially occurs during acute infection(13–14). Kitchen et. al. and others have also
shown that HIV is capable of infecting DP cells both in vitro and in vivo(15–19). Since DP
cells are located at the sites of active HIV infection, express the appropriate co-receptors and
are capable of being infected, DP cells may be important targets of acute HIV infection.
The ability of the immune system to quickly respond during acute HIV infection and thereby
decrease viral loads to low levels is believed to be an important determinant of long term
prognosis(20). Interestingly, Howe and collaborators have shown that HIV infected patients
possess circulating HIV-specific DP T-cells during the acute phase(21). These HIV-specific
DP cells expressed interferon-γ and were either co-expressing IL-2 or a marker for
degranulation (CD107a), and patients were more likely to have bifunctional DP cells than
either bifunctional CD4 or CD8 T-cells. Simultaneous expression of 3 or more functions at a
time within HIV and SIV-specific CD4 and CD8 T-cells has previously been associated with
improved disease outcomes(22–26). CD4 and CD8 T-cell proliferation in response to HIV
antigens has also been associated with better HIV disease status(27–28). Therefore, in
addition to the possibility of being a target of acute HIV infection, DP cells may represent an
important component of the HIV-specific cellular immune response. At present, little is
known about the breadth and functional profile of the DP response to HIV. As a result, we
sought to determine the ability of circulating DP cells to respond to HIV antigens with a
wide range of functionalities during the acute phase of HIV infection. Finally, we went on to
compare these acute responses with those observed in a group of HIV-1 controllers.
Materials and Methods
Subjects
Persons with acute HIV infection were identified based on clinical presentation or by
screening conducted by the state of North Carolina’s Screening and Tracing Active
Transmission (STAT) Program that has identified individuals with acute HIV infections
(AHI) since 2002. Subjects are identified as being acutely infected through a combination of
reported symptoms and serology(29). Acutely infected patients were then referred for
further evaluation at either Duke University or the University of North Carolina-Chapel Hill.
Following the provision of written informed consent, the referred patients were enrolled in
either studies of antiretroviral treatment or an untreated longitudinal study (depending on
patient choice) if they were 1) EIA Negative and nucleic acid amplification test (NAT)
positive 2) EIA positive, NAT positive, Western Blot negative/indeterminate or 3) EIA
positive, NAT positive, Western Blot positive and documented EIA negative within 45 days.
Thirty patients who had been infected a median of 43 (range 22–105) days before entry were
studied (Table 1)(29). Due to the study location, all 30 patients were presumed to have been
infected with HIV-1 clade B viruses. At study entry, blood samples were acquired from
these patients and peripheral blood mononuclear cells (PBMCs) were isolated using standard
density gradient centrifugation. Isolated PBMCs were cryopreserved in fetal calf serum
(FCS) supplemented with 10% DMSO and stored in vapor phase liquid nitrogen within 8
hours from collection. Viral load and CD4 counts were also obtained at study entry. This
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acute patient cohort had a median viral load of 259789.5 (range 688–1,1503,872) copies/mL
and a median CD4 count of 476.5 (range 6–1175) cells/mm3.
Additionally, 9 virus controllers were separately recruited from the Duke Adult Infectious
Diseases Clinic with informed consent under Duke University Medical Center IRB
approval. Virus controllers were required to have been diagnosed as HIV positive for greater
than 1 year, be antiretroviral therapy naïve, have CD4 counts >600 cells/mm3 blood and
have been controlling virus replication to less than 2,700 viral RNA copies/mL blood (Table
2)(30–32).
Peptides
Fifteen amino acid peptides overlapping by 11 amino acid residues representing the HIV-1
Clade B consensus sequences of ENV (#9480), Gag (#8117), Nef (#5189), Pol (#6208), Rev
(#6445), Tat (#5138), VPR (#6447) and VPU (#6444) were obtained from the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. Individual
peptides were resuspended in DMSO and pooled, at a final concentration of 500µg/mL, into
a total of six peptide pools representing gp120, gp41, Gag, Pol peptides #5461–5585, Pol
peptides #5586–5709, and a combination of Nef, Rev, Tat, VPR and VPU (VVNRT).
Proliferation Assays
Cryopreserved PBMC were thawed and washed twice with RPMI containing 10% FCS and
1% penicillin/streptomicin (R10) and enumerated using a Guava Count system (Millipore).
Following cell counting, the PBMCs were washed twice with PBS and subsequently
resuspended at 20×106 cells/ml. The cells were stained with Carboxyfluorescein
succinimidyl ester (CFSE) for 8 minutes mixing once at 4 minutes(33). CFSE staining was
quenched with 100% human serum for 2 minutes, and after washing with PBS, the cells
were resuspended in R10 containing human serum. CFSE stained cells were then plated at
1×106 cells/mL and stimulated with peptide pools representing HIV GP120, GP41, Gag, Pol
pool 1, Pol pool 2, VVNRT(1 ug/mL) or anti-CD3 (eBioscience) and -CD28 (BD
Biosciences) antibodies. Stimulated cells were then incubated at 36°C with 5% CO2 for 6
days. Following 6 days of stimulation, the cultures were washed twice with PBS and stained
with a violet vital dye (Invitrogen) for 20 minutes at room temperature in the dark. Cells
were again washed twice with PBS and then stained with anti-CD3 APC-Cy7 (BD
Biosciences; clone SK7), -CD4 PE-Cy5.5 (eBioscience; OKT4) and -CD8 Qdot605
(Invitrogen; 3B5) antibodies for 20 minutes at room temperature in the dark. Following
antibody staining, the cells were washed thrice with PBS and fixed with 1%
paraformaldehyde. Stained and fixed cells were then refrigerated in the dark until
acquisition.
Intracellular Cytokine Staining Assays
Cryopreserved PBMC were thawed, resuspended at 2x106 cells/mL in R10 and rested
overnight at 36°C with 5% CO2. After the overnight rest, the PBMCS were counted and
resuspended at 1×106 cells/mL in R10. Cells were then stimulated for 6 hours at 36°C with
5% CO2with peptide pools representing CMV pp65, HIV GP120, GP41, Gag, Pol pool 1,
Pol pool 2 or VVNRT (1 ug/mL). Stimulations were performed in the presence of 1ug/mL
each of anti- CD28 (BD Biosciences; L293) and CD49d (BD Biosciences; L25) antibodies,
anti-CD107a PE-Cy5(eBioscience; H4A3), 5ug/mL Brefeldin A (Sigma-Aldrich) and 1 ug/
mL Monensin (BD Biosciences). Following the stimulation, the cells were washed with PBS
containing 1% FCS and surface stained with Aqua Blue vital dye (Invitrogen), anti-CD4 PE
Cy5.5 (eBioscience; OKT4), -CD8 Qdot605 (Invitrogen; 3B5), -CD27 PE-Cy7 (BD
Biosciences; M-T271), -CD57 Qdot565 (AbD Serotec; TB01) and –CD45RO PE-TR
(Beckman Coulter; UCHL1) for 20 minutes at room temperature in the dark. Following
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surface staining, the cells were washed again with PBS containing 1% FCS, and then
subsequently fixed and permeabilized with cytofix/cytoperm and perm/wash buffer (BD
Biosciences) for 20 minutes and washed twice. Following the fix/perm step, cells were
stained intracellularly with anti-CD3 Qdot655 (Invitrogen; S4.1), -IFN-γ Alexa700 (BD
Biosciences; B27), -IL-2 APC (BD Biosciences; MQ1-17H12) -MIP-1β FITC (R&D
Systems; 24006), and –perforin PE (Cell Sciences;B-D48) for 20 minutes at room
temperature in the dark. Subsequent to intracellular staining, cells were washed with perm/
wash buffer and then fixed with 1% paraformaldehyde. Following fixation, cells were
refrigerated in the dark until acquisition.
Flow Cytometry Acquisition and Analysis
Within 18 hours of staining, fully stained cells from the proliferation and intracellular
cytokine staining (ICS) assays were acquired on a custom LSRII (BD Biosciences) using
FACSDiva. Following acquisition, flow data was analyzed using FlowJo software v.9.3.2
(TreeStar). For all assays, gates were set to include singlet events, live CD3+ cells,
lymphocytes and CD4+/CD8+/CD4+CD8+ subsets. For the proliferation assays, CFSElow
populations were then identified from each lymphocyte subset (Supplemental Figure 1A).
For the ICS assays, the naïve population (CD27+CD45RO−) was identified and excluded
from each lymphocyte subset. Within the memory population, cellular function positive
populations were identified individually for all cellular functions except perforin, which was
only defined as positive if both perforin+ and IFN-γ+ (Supplemental Figure 1B). Using a
boolean gating strategy, the 32 combinations of the 5 cellular functions were identified.
Based on these frequencies, we also calculated the total frequency of families of subsets
expressing the same number of functions.
Statistical Analysis
For the proliferation assays, relative proliferation values were obtained by subtracting the
average CFSElow population frequency of a patient samples’ two unstimulated wells from
the CFSElow population frequency following stimulation, and then dividing the resulting
value by the average CFSElow population frequency of a patient samples’ two unstimulated
wells. For the intracellular cytokine staining assays, Pestle was used for background
subtractions and Prism (Graphpad) and SPICE were used for frequency analysis. PESTLE
and SPICE were kindly provided by Dr. M. Roederer Vaccine Research Center, NIH,
Bethesda, MD.
DP response ratios were calculated by first multiplying each patients’ frequency of HIV-
specific DP, CD4 and CD8 T-cells by the mean cell count in the DP, CD4 and CD8
compartments for each stimulation condition to obtain a normalized HIV-specific DP, CD4
and CD8 cell count. The normalized HIV-specific DP cell count was then divided by the
sum of the normalized HIV-specific DP, CD4 and CD8 cell counts to give the DP response
ratio.
Comparisons of responses within patient groups were performed using a Wilcoxon Matched
Pairs test (Prism). Comparison across patient groups used a Mann-Whitney U test (Prism).
Regression analyses were performed using a linear regression (Prism). No adjustments for
multiple comparisons were performed and p values should be interpreted with this in mind.
Results
HIV-specific Proliferation of DP cells
Previous studies reported a correlation between the magnitude of HIV-specific proliferation
of T-cells and improved disease outcomes. Nonetheless, HIV-specific proliferation of DP
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cells has not been previously examined. Therefore, PBMCs from HIV+ patients were
analyzed for their proliferative ability in response to stimulation with peptides representing
the HIV clade B consensus peptide sequence. Following 6 days of stimulation, CD4+CD8−
(CD4), CD4+CD8+ (DP) and CD4−CD8+ (CD8) populations were identified by flow
cytometry (Supplemental Figure 1A). The loss of CFSE staining was used to indicate cells
within these populations which had undergone proliferation during the stimulation(33). As
expected, we observed proliferative responses to the HIV proteome within both the CD4 and
CD8 compartments of the acutely infected subjects. The relative proliferation within the
CD8 compartment was greater than that seen in the CD4 compartment for both the acute
(median, range 1.78, −4.93–25.5 vs. 0.93,−3.86–31.22) and controller patients (3.28, −0.19–
29.69 vs. 0.55, −0.32–20.89), although this difference was only significant in the controller
cohort (Figure 1A). In both acutely infected (3.78, −3.42–36.36) and controller patients
(6.61, −0.13–98.13), we observed significantly greater relative proliferation within the DP
compartment following HIV antigen stimulation than the CD4 compartment. DP
proliferative responses were also higher than those observed in the CD8 compartments of
both cohorts, but reach statistical difference only in the acute cohort (p= 0.01). Next, we
determined the portion of the total T-cell proliferative response to HIV which was
attributable to the DP compartment in the acute and controller cohorts, a calculation we call
the DP response ratio. In both cohorts, the median proliferative DP response ratio was
approximately 16% (range 0–78; 0–39) (Figure 1B). In 5 of 30 acute patients the DP
response ratio was greater than 40%. We also sought to determine if there was a relationship
between the time since infection and the magnitude of the proliferative response. There was
no correlation between the CD4 proliferative response and time following infection (Figure
1C). However, the HIV specific proliferative response within the DP and CD8
compartments increases with time since infection (p = 0.0198, 0.0406), suggesting that both
the DP and CD8 proliferative responses gain strength as the immune system partially
controls viral replication (Figure 1D and E). Meanwhile, the magnitude of the HIV-specific
proliferative response within the controller cohort did not correlate with viral loads within
these patients (p = 0.6312).
Polyfunctionality of HIV-specific DP cells
The polyfunctionality of HIV-specific cells was analyzed by staining for the expression of
CD107a, IFN-γ, IL-2, MIP-1β and perforin after a six hour stimulation. HIV-specific
functionality was determined according to the gating strategy displayed in supplemental
figure 1B. Following the identification of each individual functional population, Boolean
gating was applied to identify cells expressing all possible combinations of the 5 functions.
We observed a significantly higher frequency of CD8 T-cells expressing 3 or more functions
in the acutely infected group than we observed within the CD4 compartment (Figure 2A).
HIV-specific multifunctional cells within the DP compartment (20, −0.19–100) were
significantly more frequent than in the CD8 compartment (0.34, 0.01–24.84) in the acute
infection group (p = 0.0002). Of interest, 100% of patient Z68’s DP cells were specific for
HIV and multifunctional at study entry.
Using the multifunctional response, we again compared the DP response ratios across
cohorts to determine the fraction of all HIV-specific multifunctional T-cells which reside
within the DP compartment (Figure 2B). The acute cohort had a median multifunctional DP
response ratio of 73% (0–92%) while the controllers exhibited a median of 2% (0–100%). It
is notable that the controllers exhibited an extremely variable DP response ratio with the
majority well below the acute cohorts’ median and two patients presenting a DP ratio of
100%. Due to this high variability, the response ratios of the two groups only trended
towards a significant difference (p = 0.1677).
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In order to understand the differentiation stage of the whole and HIV-1-specific
multifunctional DP cell subsets, we also examined their CD27, CD45RO, and CD57
expression. Within the general memory population of the CD4, DP and CD8 memory
compartments (Supplemental Figure 2A-F), we observed that the CD4 memory
compartment was predominantly CD27+CD45RO+CD57−; the CD8 memory compartment
was evenly distributed between CD27 and CD45RO expression status with the frequency of
cells lacking CD57 expression being approximately two-fold higher than those displaying
CD57 expression. The DP compartment was often intermediate to the frequencies displayed
in either the CD4 or CD8 compartments but more closely resembled the CD8 compartment.
When the HIV-1-specific subsets were analyzed, we found that in both the acute and
controller cohorts, a median of 92% (33–99%; 50–100%) of multifunctional DP cells lacked
CD57 expression and therefore were not terminally differentiated (Figure 2C). Within the
time span covered by our acute cohort, there were no significant correlations between the
frequencies of CD4, DP or CD8 multifunctional cells and time post-infection (Supplemental
Figure 3A, B and C). Conversely, the frequency of HIV-specific multifunctional DP cells
within the controller cohort correlated with the viral loads within these patients (p = 0.0282).
Antigen-Specific Contribution to HIV-specific responses
Next, we sought to identify the antigenic regions responsible for evoking the proliferation
and multifunctionality observed within the DP compartment. Within the acute HIV infection
cohort, we observed no significant antigen-specific differences in proliferative capacity of
the DP cells (Figure 3A). On the other hand, the controllers’ DP cells focused on all non-
Env peptide pools (Figure 3B). In fact, the DP proliferative response to Gag was
significantly higher within the controller cohort than within the acute cohort (p = 0.0437).
All other antigen-specific responses were not significantly different between the patient
cohorts (p-values summarized in Supplemental Table 1).
In contrast to their proliferative response, the acute patients’ multifunctional response was
most pronounced to VVNRT, though responses were robust to most of the peptide pools
(Figure 3C). Meanwhile, the controllers’ multifunctional response did not focus on an
individual HIV antigen pool (Figure 3D). We compared the multifunctional responses to
each antigen between patient cohorts and observed that they were significantly higher
among the acute patients than the controllers for all peptide pools except the Pol pool 1,
which displayed a trend towards significance (p-values summarized in Supplemental Table
1).
We also compared the proliferative and functional responses across assays for the two
peptide pools (Gag and VVNRT) that generated the strongest functional and proliferative
responses. This analysis revealed no correlation between the level of proliferating DP cells
and the frequency of multifunctional DP cells (Figure 4A and B). This was observed in both
the acute and controller cohorts.
Relationship between responses within the DP subset and the CD4+ and CD8+ T-cell
subsets
It is not clear if DP cells leave the thymus as DP cells or if they are derived in the periphery
from the CD4 and/or CD8 compartments. In order to gain some insight into the origins of
the DP response, we also determined the degree to which the magnitude of HIV-1-specific
DP responses resembled that found within either the CD4 or CD8 compartments. Within the
acute cohort, the level of proliferated DP cells was directly related to the proliferation
observed within the CD4 compartment following stimulation with each HIV antigen (Figure
5A and not shown). Furthermore, the magnitude of DP proliferation following stimulations
with Gag, both Pol pools and VVNRT also correlated with the proliferation observed in the
Frahm et al. Page 6













CD8 compartment (Figure 5A and not shown). Similarly, the controller DP proliferative
response correlated with the CD4 response following stimulations with Gag and both Pol
pools (Figure 5B and not shown). While the DP anti-Gag and VVNRT proliferative
response correlated with the observed CD8 proliferation. Conversely, there were no
significant correlations between the acute DP multifunctional response and the CD4
response. The magnitude of the acute anti-GP120 multifunctional DP response did correlate
with the multifunctional frequencies observed in the CD8 compartment (Figure 5C and not
shown). Meanwhile, the controller DP multifunctional responses did not correlate with any
CD4 or CD8 multifunctional responses (Figure 5D and not shown). The p-values obtained
from each of these comparisons are summarized in Supplemental Table 1.
Discussion
Relative to the extensive analysis of the CD4+ and CD8+ T-cell compartments, the role of
circulating DP cells in immune responses to pathogens and cancer has rarely been studied.
As a result, their immune function is poorly understood. In this study, we present the first
ever evidence of antigen-specific DP cells simultaneously producing 3 or more functions.
Previously, a cohort of patients recently infected with HIV-1 was shown to contain DP cells
which produced IFN-γ alone or in combination with either IL-2 or expression of CD107a in
response to HIV(21). This work was performed at the level of the entire HIV proteome,
leaving the antigen-specific breadth of DP cells unknown. Additionally, we present the first
ever examination of HIV-specific DP cells within patients who naturally control HIV-1
infection. In this study, we sought to determine the antigen specificity of DP cells and if DP
cells were capable of mounting a wide variety of response modalities (CD107a, IFN-γ, IL-2,
MIP-1β, and/or perforin as well as proliferation) or were restricted to a narrow range of
response types. This was done using peptide pools representing the majority of the HIV
genome to stimulate cells isolated from acutely infected HIV patients. This study has shown
that within these patients, DP cells represent an immune subset which is capable of
proliferation and mounting a multifunctional response. We show for the first time that
antigen-specific DP cells are capable of expressing 3 or more functions at a time. In fact,
within the acute cohort studied here, anti-HIV T-cells expressing all 5 functions were almost
exclusively DP cells (data not shown). Moreover, the multifunctional DP cells from the
acute cohort were primarily focused on the VVNRT peptide pool, while the controller
multifunctional DP cells were less focused in their antigen specificity.
The presence of multifunctional cells within the CD8 compartment during chronic infection
has previously been shown to correlate with improved disease outcomes(22). Therefore, it
will be important to track the DP response in treatment naïve patients to determine if
multifunctional DP cells are as protective as multifunctional CD8 cells. Interestingly, the
presence of multifunctionality in the DP population did not correlate with multifunctionality
in the CD8 compartment. Our previous findings have shown that it may take as long as 55
weeks to develop significant multifunctional CD8 responses(34). As a result, it is unclear if
there is truly a lack of a relationship between DP and CD8 multifunctionality or if
multifunctionality within the DP compartment may precede development of CD8
multifunctionality. Nonetheless, within our limited cohort of controllers there was a
correlation between the frequency of multifunctional DP cells and lower viral loads at the
time of sample acquisition. This suggests that multifunctional DP cells may have an impact
on the successful control of virus replication.
We have shown that HIV-specific DP cells display both proliferative and multifunctional
capabilities. These two qualitative aspects of the anti-HIV immune response have previously
been correlated with improved disease outcomes when examined within other T-cell
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compartments. It is important to note that the samples in this study were obtained while the
patients’ immune response would be expected to establish a partial control of viral
replication toward the viral set point. Therefore, the DP responses described here are
temporally associated with an expected decline in viral load and consequently may be
important mediators of the temporary viral control experienced late in acute infection. For
that reason, it will be important to isolate HIV-specific DP cells in order to test their ability
to inhibit HIV in vitro either through direct inhibition of viral replication, by cytotoxic
killing of HIV infected cells and/or stimulation of antibody dependent cellular cytotoxicity.
Additionally, recent improvements in humanized mouse models may allow the selective
addition and subtraction of DP cells in order to determine the role DP cells may play in the
initial decline in viral loads following acute infection(35–38). If DP cells are able to not just
respond to HIV antigens but in fact inhibit HIV, then it is important to note that a
therapeutic vaccine trial has shown the ability to significantly increase HIV-specific IFN-γ
production by DP cells in chronically infected patients with a single intramuscular
injection(39). This vaccine trial was able to demonstrate that not only are HIV-specific DP
cells present in chronic infection, but that memory T-cell responses result in the expansion
of HIV-specific DP cells in addition to traditional CD4 and CD8 expansion. Therefore, DP
cells may need to be considered in the development of therapeutic HIV vaccines.
Additionally, Pahar and colleagues have shown that DP cells are highly enriched in the gut,
which is an important target site for protective HIV vaccine development(13). Our study
revealed that the circulating HIV-specific multifunctional DP population generally lacks
expression of CD57 and is therefore not terminally differentiated. Thus, it may be possible
to generate a long lasting protective DP memory pool. Unfortunately, Brenchley et.al. have
shown that CD57− memory T-cells preferentially harbor HIV(18). Therefore, the DP cells
we may want to elicit for protective immunity may also be the subset of DP cells HIV
prefers to infect. As a result, extensive examination of dynamics between DP mediated anti-
HIV responses and infectability may be necessary.
Given previous work showing that DP cells are generally highly differentiated, our
observation that they show evidence of proliferation following 6 days raises important
questions about DP cell origins, at least in the HIV-1 infection model. Since a portion of DP
cells resemble central memory T-cells or even naïve T-cells, it is possible that the DP
population is a self-sustaining population(21). Alternatively, a portion of single positive
CD4 and/or CD8 T-cells could transition to DP status following antigenic activation and
differentiation. In fact, previous work has shown that heavy stimulation (CD3/28, SEB, etc.)
of CD8 T-cells sustained over multiple days causes dim expression of CD4 (16, 40–41). We
observed CD4bright in addition to CD4dim DP cells within both stimulated and unstimulated
conditions, therefore sustained strong stimulation of CD8 cells is unlikely to explain the
origin of the DP cells described in this study. Additionally, DP cells were also present and
highly active in the ICS assay for which stimulations only lasted 6 hours rather than multiple
days as in the above studies. If the HIV-specific DP cells we observe are originating from a
single positive population, then the strong correlation between proliferated CD4 and DP
cells means that it is likely that the CD4 compartment would be the primary source.
Similarly, Colombatti and colleagues’ work showing that DP cells show greater clonal
similarity with CD4 cells than CD8 cells further supports this hypothesis(42).
In summary, we have demonstrated that DP cells are capable of mounting a large and highly
diversified response to HIV antigens. Additionally, the DP response is maintained in viral
controllers and similar responses within the CD4 and CD8 compartments have previously
been correlated with improved disease outcomes. Therefore, it is important that this study
form the basis of further work delineating the effect this response has on viral replication
and long term disease outcomes. Furthermore, these DP cells may be an important vaccine
target, which means we must work to more fully understand DP cell origins and
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development. In total, we have established DP cells as a major responding population to
acute HIV infection and established a basis for extensive exploration of their origins and
role in successfully combating HIV and other pathogens.
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Figure 1. Total HIV-Specific Proliferation
A, Cells were stained with CFSE and stimulated for 6 days with peptide pools representing
the HIV proteome. The HIV-specific relative proliferation was calculated for each T-cell
subtype and plotted for each patient in the acute and chronic cohorts. B, The percentage of
the total anti-HIV proliferative response coming from the DP compartment was calculated
for each patient in the acute and chronic cohorts. C, The days post infection at which an
acute blood sample was drawn was plotted against the HIV-specific relative proliferation in
the CD4 compartment D, DP compartment E, CD8 compartment
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Figure 2. Total HIV-Specific Multifunctionality
A, Cells were stimulated for 6 hours with peptide pools representing the HIV proteome and
then expression of CD107a, IFN-γ, IL-2, MIP-1β and perforin. Using Boolean gating
expression of all possible combinations of these functions was determined. The HIV-
specific frequency of cells expressing 3, 4 or 5 of these functions within each T-cell subtype
was plotted for each patient. B, The percentage of the total 3, 4 or 5 function response
coming from the DP compartment was calculated for each patient in the acute and chronic
cohorts. C, The percentage of multifunctional DP cells lacking expression of CD57.
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Figure 3. HIV Antigen Specific Responses
A, The relative proliferation of the DP compartment against each HIV antigen pool for
patients in the acute cohort. B, within the controller cohort. C, The frequency of antigen
specific 3, 4 or 5 function memory T cells responding to each HIV antigen pool in the acute
cohort. D, within the controller cohort.
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Figure 4. Relationship between Multifunctionality and Proliferation
A, The frequency of antigen specific 3, 4 or 5 function DP cells is plotted against the relative
proliferation of DP cells in response to gag stimulation. B, in response to VVNRT
stimulation.
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Figure 5. CD4 or CD8 Responses vs. DP Responses
A, The antigen specific relative proliferation in the CD4 or CD8 compartment for each
patient is plotted against that patient’s antigen specific relative proliferation in the DP
compartment for patients in the acute cohort. B, for patients in the controller cohort. C, The
antigen specific frequency of 3, 4 or 5 function CD4 or CD8 cells is plotted against that
patient’s antigen specific frequency of 3, 4 or 5 function DP cells for patients in the acute
cohort. D, for patients in the controller cohort.
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VC10 2670 902 3.72
VC11 2020 924 4.00
VC16 519 628 2.06
VC18 <48 1514 1.98
VC20 601 627 2.65
VC23 424 806 4.36
VC24 894 643 2.24
VC26 118 668 2.43
VC27 2690 816 3.33
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